Full-Year Outlook Narrowed at Top and Bottom Ends "The sales growth is driven by increasing demand for our GLP-1-based ...

Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 ...

Novo Nordisk is the company that makes the Ozempic and Wegovy drugs, part of the wildly popular GLP-1 class of drugs that have proven effective in reducing weight and treating diabetes. Demand has ...

It took decades to get to the GLP-1 breakthrough in obesity treatment. Now, the biopharma industry is clamoring over the field's next frontier: staving off the losses ...

When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated ...

Nutritionists say there’s an easy, natural and cheaper way to get the same results as prescription weight loss drugs.

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Amid the rise of gut health and GLP-1 drugs in the UK, Potina is making high-fibre banana oat milks for improved children's ...

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...

On November 5, the US Food and Drug Administration (FDA) updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a warning about pulmonary aspiration during general ...